Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy - Cancer Therapy Advisor

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Targeted drug delivery strategies for precision medicines

Page 1526 – Cancer Therapy Advisor

Radiotherapy as a tool to elicit clinically actionable signalling

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal

img_001.jpg

Cancers, Free Full-Text

Efficacy of lapatinib monotherapy on occult breast cancer

Cancers, Free Full-Text

Neoadjuvant Therapy in HER2-Positive Breast Cancer: Ready for

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies

January 2011 - Oncology Practice Digital Network

Early Lapatinib-Induced Skin Rash Predicts Better Survival With

Lapatinib with trastuzumab for HER2-positive early breast cancer

Early Adverse Events predict Survival Outcomes in HER2-positive